However, although SGLT2 inhibitors are definitely beneficial in suppressing the progression of diabetic nephropathy, it is still unclear whether they are also effective for patients with CKD who do not have albuminuria. This evidence concerns the gene SLC5A2 and diabetic kidney disease.